Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
RationaleTobacco withdrawal is characterized by a negative mood state and relatively mild somatic symptoms. Increased noradrenergic transmission has been reported to play an important role in opioid withdrawal, but little is known about the role of noradrenergic transmission in nicotine withdrawal.ObjectivesThe aim of these experiments was to investigate the effects of prazosin, clonidine, and propranolol on the negative mood state and somatic signs associated with nicotine withdrawal in rats.MethodsA discrete-trial intracranial self-stimulation procedure was used to assess the negative affective state of nicotine withdrawal. Elevations in brain reward thresholds are indicative of a deficit in brain reward function.ResultsIn all the experiments, the nicotinic acetylcholine receptor antagonist mecamylamine (3 mg/kg) elevated the brain reward thresholds of the nicotine-treated rats and did not affect those of the control rats. The α1-adrenergic receptor antagonist prazosin (0.0625 and 0.125 mg/kg) dose-dependently attenuated the elevations in brain reward thresholds associated with precipitated nicotine withdrawal. The α2-adrenergic receptor agonist clonidine (10–40 μg/kg) and the nonselective β-adrenergic receptor antagonist propranolol (2.5–10 mg/kg) did not attenuate the elevations in brain reward thresholds associated with nicotine withdrawal. Furthermore, mecamylamine (2 mg/kg) induced more somatic signs in the nicotine-treated rats than in the control rats. Clonidine and propranolol, but not prazosin, decreased the total number of somatic signs associated with nicotine withdrawal.ConclusionBlockade of α1-adrenergic receptors attenuates the deficit in brain reward function associated with nicotine withdrawal. Antagonism of β-adrenergic receptors or stimulation of α2-adrenergic receptors attenuates the somatic symptoms of nicotine withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 2×
“shown to improve smoking cessation rates and decrease tobacco withdrawal symptoms such as depression, difficulty concentrating, and irritability (Hurt et al. 1997; Jorenby et al. 1999; Shiffman et al. 2000).”
BackgroundAntidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
β-Adrenergic activation and memory for emotional events
Cahill, L., Prins, B., Weber, M., & McGaugh, J. L. (1994) · Nature · doi:10.1038/371702a0 · Cited by 1,271
Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction
Koob, G. F., & Le Moal, M. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1442 · Cited by 963 · cited 1×
“The negative emotional state associated with tobacco withdrawal provides a powerful motivation for the continuation of smoking (Bruijnzeel and Gold 2005; Koob and Le Moal 2005 ).”
BackgroundDramatic decreases in brain reward function during nicotine withdrawal
Epping-Jordan, M. P., Watkins, S. S., Koob, G. F., & Markou, A. (1998) · Nature · doi:10.1038/30001 · Cited by 674
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567 · cited 1×
“However, selective serotonin reuptake inhibitors such as fluoxetine, paroxetine, and sertraline do not improve smoking cessation rates (Hughes et al. 2007).”
BackgroundPharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
Hyttel, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00004 · Cited by 492 · cited 2×
“One of the compounds that has been investigated as a smoking cessation aid is the antidepressant and relative selective norepinephrine reuptake inhibitor nortriptyline (5-HT, 570; NE, 3.4; DA, 3,500, IC50, reuptake inhibition in vivo; Hyttel 1994).”
BackgroundInfluentialNoradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion
Delfs, J. M., Zhu, Y., Druhan, J. P., & Aston-Jones, G. (2000) · Nature · doi:10.1038/35000212 · Cited by 462
Symptoms of Tobacco Withdrawal: A Replication and Extension
Hughes, J. R. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810250054007 · Cited by 449
Neurobiological evidence for hedonic allostasis associated with escalating cocaine use
Ahmed, S. H., Kenny, P. J., Koob, G. F., & Markou, A. (2002) · Nature Neuroscience · doi:10.1038/nn872 · Cited by 389 · cited 2×
“Animals that have long access (6 h/day) to cocaine, but not animal with short access (1 h/day), display an escalation of cocaine intake and a gradual elevation in brain reward thresholds (Ahmed et al. 2002).”
Background
Cited by
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432
“, 2010), which an be modeled in rodents using techniques that have been well alidated for other indices of affective modulation (Barr et al., 2000; ruijnzeel et al., 2010).”
BackgroundReward, addiction, withdrawal to nicotine
De Biasi, M., & Dani, J. A. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113734 · Cited by 366
“Besides DA, other neurotransmitters, such as serotonin and norepinephrine, known to mediate the manifestations of withdrawal from other drugs may play a role (Bruijnzeel et al. 2010, Fletcher et al. 2008, Semenova & Markou 2010, Slotkin & Seidler 2007).”
BackgroundAddiction and Stress: An Allostatic View
Koob, G. F., & Schulkin, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.008 · Cited by 315
Common brain mechanisms of chronic pain and addiction
Elman, I., & Borsook, D. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.027 · Cited by 303
McKee, S. A., Potenza, M. N., Kober, H., Sofuoglu, M., Arnsten, A. F., Picciotto, M. R., Weinberger, A. H., Ashare, R., & Sinha, R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114562091 · Cited by 75
“…2007), reduce conditioned place preference to nicotine (Forget et al., 2009), attenuate nicotine withdrawal-induced deficits in brain reward thresholds (Bruijnzeel et al., 2010), and reduce somatic signs of nicotine withdrawal in animals and humans (Bruijnzeel et al., 2010; Gourlay et al., 2004).”
Background
Metadata
- Authors
- Bruijnzeel, A. W., Bishnoi, M., van Tuijl, I. A., Keijzers, K. F. M., Yavarovich, K. R., Pasek, T. M., Ford, J., Alexander, J. C., & Yamada, H.
- Venue
- Psychopharmacology
- Published
- 2010-08-10
- Volume
- 212
- Issue
- 4
- Pages
- 485-499
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1994725667
- Cited by
- 53
- References
- 25
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. https://app.cochat.ai/papers/10.1007/s00213-010-1970-0
- The paper
- Bruijnzeel, A. W., Bishnoi, M., van Tuijl, I. A., Keijzers, K. F. M., Yavarovich, K. R., Pasek, T. M., Ford, J., Alexander, J. C., & Yamada, H. (2010). Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology. https://doi.org/10.1007/s00213-010-1970-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.